Global Huntington's Disease Therapeutics Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 Huntington's Disease Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Huntington's Disease Therapeutics Market Size Growth Rate by Product
- 1.4.2 Antidopaminergics
- 1.4.3 Anticonvulsants
- 1.4.4 Antipsychotics
- 1.4.5 Antidepressants
- 1.5 Market by End User
- 1.5.1 Global Huntington's Disease Therapeutics Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Diagnostic Centers
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Huntington's Disease Therapeutics Market Size
- 2.1.1 Global Huntington's Disease Therapeutics Revenue 2014-2025
- 2.1.2 Global Huntington's Disease Therapeutics Sales 2014-2025
- 2.2 Huntington's Disease Therapeutics Growth Rate by Regions
- 2.2.1 Global Huntington's Disease Therapeutics Sales by Regions
- 2.2.2 Global Huntington's Disease Therapeutics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Huntington's Disease Therapeutics Sales by Manufacturers
- 3.1.1 Huntington's Disease Therapeutics Sales by Manufacturers
- 3.1.2 Huntington's Disease Therapeutics Sales Market Share by Manufacturers
- 3.1.3 Global Huntington's Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Huntington's Disease Therapeutics Revenue by Manufacturers
- 3.2.1 Huntington's Disease Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Huntington's Disease Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Huntington's Disease Therapeutics Price by Manufacturers
- 3.4 Huntington's Disease Therapeutics Manufacturing Base Distribution, Product Types
- 3.4.1 Huntington's Disease Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Huntington's Disease Therapeutics Product Type
- 3.4.3 Date of International Manufacturers Enter into Huntington's Disease Therapeutics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Huntington's Disease Therapeutics Sales by Product
- 4.2 Global Huntington's Disease Therapeutics Revenue by Product
- 4.3 Huntington's Disease Therapeutics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Huntington's Disease Therapeutics Breakdown Data by End User
6 North America
- 6.1 North America Huntington's Disease Therapeutics by Countries
- 6.1.1 North America Huntington's Disease Therapeutics Sales by Countries
- 6.1.2 North America Huntington's Disease Therapeutics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Huntington's Disease Therapeutics by Product
- 6.3 North America Huntington's Disease Therapeutics by End User
7 Europe
- 7.1 Europe Huntington's Disease Therapeutics by Countries
- 7.1.1 Europe Huntington's Disease Therapeutics Sales by Countries
- 7.1.2 Europe Huntington's Disease Therapeutics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Huntington's Disease Therapeutics by Product
- 7.3 Europe Huntington's Disease Therapeutics by End User
8 Asia Pacific
- 8.1 Asia Pacific Huntington's Disease Therapeutics by Countries
- 8.1.1 Asia Pacific Huntington's Disease Therapeutics Sales by Countries
- 8.1.2 Asia Pacific Huntington's Disease Therapeutics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Huntington's Disease Therapeutics by Product
- 8.3 Asia Pacific Huntington's Disease Therapeutics by End User
9 Central & South America
- 9.1 Central & South America Huntington's Disease Therapeutics by Countries
- 9.1.1 Central & South America Huntington's Disease Therapeutics Sales by Countries
- 9.1.2 Central & South America Huntington's Disease Therapeutics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Huntington's Disease Therapeutics by Product
- 9.3 Central & South America Huntington's Disease Therapeutics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Huntington's Disease Therapeutics by Countries
- 10.1.1 Middle East and Africa Huntington's Disease Therapeutics Sales by Countries
- 10.1.2 Middle East and Africa Huntington's Disease Therapeutics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Huntington's Disease Therapeutics by Product
- 10.3 Middle East and Africa Huntington's Disease Therapeutics by End User
11 Company Profiles
- 11.1 F. Hoffmann-La Roche
- 11.1.1 F. Hoffmann-La Roche Company Details
- 11.1.2 Company Business Overview
- 11.1.3 F. Hoffmann-La Roche Huntington's Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 F. Hoffmann-La Roche Huntington's Disease Therapeutics Products Offered
- 11.1.5 F. Hoffmann-La Roche Recent Development
- 11.2 H. Lundbeck
- 11.2.1 H. Lundbeck Company Details
- 11.2.2 Company Business Overview
- 11.2.3 H. Lundbeck Huntington's Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 H. Lundbeck Huntington's Disease Therapeutics Products Offered
- 11.2.5 H. Lundbeck Recent Development
- 11.3 Prana Biotechnology
- 11.3.1 Prana Biotechnology Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Prana Biotechnology Huntington's Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Prana Biotechnology Huntington's Disease Therapeutics Products Offered
- 11.3.5 Prana Biotechnology Recent Development
- 11.4 Teva Pharmaceutical Industries
- 11.4.1 Teva Pharmaceutical Industries Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Teva Pharmaceutical Industries Huntington's Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Teva Pharmaceutical Industries Huntington's Disease Therapeutics Products Offered
- 11.4.5 Teva Pharmaceutical Industries Recent Development
- 11.5 Horizon Pharma
- 11.5.1 Horizon Pharma Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Horizon Pharma Huntington's Disease Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Horizon Pharma Huntington's Disease Therapeutics Products Offered
- 11.5.5 Horizon Pharma Recent Development
12 Future Forecast
- 12.1 Huntington's Disease Therapeutics Market Forecast by Regions
- 12.1.1 Global Huntington's Disease Therapeutics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Huntington's Disease Therapeutics Revenue Forecast by Regions 2019-2025
- 12.2 Huntington's Disease Therapeutics Market Forecast by Product
- 12.2.1 Global Huntington's Disease Therapeutics Sales Forecast by Product 2019-2025
- 12.2.2 Global Huntington's Disease Therapeutics Revenue Forecast by Product 2019-2025
- 12.3 Huntington's Disease Therapeutics Market Forecast by End User
- 12.4 North America Huntington's Disease Therapeutics Forecast
- 12.5 Europe Huntington's Disease Therapeutics Forecast
- 12.6 Asia Pacific Huntington's Disease Therapeutics Forecast
- 12.7 Central & South America Huntington's Disease Therapeutics Forecast
- 12.8 Middle East and Africa Huntington's Disease Therapeutics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Huntington's Disease Therapeutics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Huntington's disease is an inherited disease that causes degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on functional abilities of the human and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When disease begins before age 20, the condition is known as juvenile Huntington's disease.
The demand for Huntington’s disease (HD) therapeutics as one of the primary growth factors for the Huntington’s disease therapeutics market. HD is equally prevalent in both males and females and affects people irrespective of their ethnicity. The disease symptoms may appear anytime in the individual’s life and the etiology is genetic. The person who inherits the mutated genes from their affected parents will probably suffer from the disease sometime in their lifetime.
The Americas is witnessing increasing incidences of HD. The availability of increased patient pool and the rise in government initiatives boost the research and development of novel therapeutics for the treatment of HD. The rising investments towards the launch of new drugs for the treatment of chorea will positively influence the growth of the Huntington’s disease therapeutics market in this region.
The global Huntington's Disease Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Huntington's Disease Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Huntington's Disease Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Huntington's Disease Therapeutics in these regions.
This research report categorizes the global Huntington's Disease Therapeutics market by top players/brands, region, type and end user. This report also studies the global Huntington's Disease Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
F. Hoffmann-La Roche
H. Lundbeck
Prana Biotechnology
Teva Pharmaceutical Industries
Horizon Pharma
Market size by Product
Antidopaminergics
Anticonvulsants
Antipsychotics
Antidepressants
Market size by End User
Hospitals
Clinics
Diagnostic Centers
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Huntington's Disease Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Huntington's Disease Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Huntington's Disease Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Huntington's Disease Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Huntington's Disease Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Huntington's Disease Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.